RARA and acute promyelocytic leukemia: In the context of treatment, the oncogenic fusion gene provides an ideal target for therapeutic intervention, since supraphysiological levels of the RAR ligand, all-trans retinoic acid (ATRA), induces degradation of the PML-RARα in APL cells and restores normal RAR transcriptional programs9,13,17.